AstraZeneca has requested Well being Canada to evaluate a brand new long-acting antibody mixture that may very well be used to stop symptomatic COVID-19.
If accepted, it will be the primary antibody safety of its variety in Canada.
Learn extra:
AstraZeneca COVID-19 drug prevents extreme illness if given early, firm says
The corporate says its medical trials confirmed the antibody therapy was nicely tolerated and diminished the danger of growing symptomatic COVID-19 by 77 per cent in comparison with a placebo.
AstraZeneca Canada says it may very well be a superb possibility for susceptible populations who aren’t in a position to develop a robust protecting response from a vaccine.
The corporate says preliminary findings present the antibodies neutralize current COVID-19 variants, together with the Delta and Mu variants.
Well being Canada has stated all COVID-19 vaccine and drug submissions might be prioritized and reviewed on an expedited timeline.
Learn extra:
AstraZeneca seeks U.S. emergency approval for COVID-19 prevention drug
© 2021 The Canadian Press
